Serum 1,5-Anhydroglucitol Serves as An Additional Biomarker for Diagnosing and Monitoring Type 2 Diabetes: Vietnamese Cohort
Abstract
Objective: The incidence of diabetes is increasing worldwide, at an incredible pace and with a substantial burden. Precise and early diagnosis of type 2 diabetes (T2D) can help patients control complications. It has been found that decreased levels of 1,5-anhydroglucitol (1,5-AG) in serum can serve as a marker for diagnosing and monitoring degrees of T2D. Our study validated the value of 1,5-AG in T2D patients in a Vietnamese population over their treatment course.
Material and Methods: A cohort of 100 participants; including 50 T2D patients and 50 healthy individuals were recruited from Da Nang hospital. Demographic features were recorded. Blood samples over the period of treatment were collected for measurement of 1,5-AG, fasting blood glucose, hemoglobin A1C (HbA1c) and fructosamine.
Results: Patients with T2D showed significant decreases in 1,5-AG compared to the control group: 10.91±6.53 µg/mL and 26.83±9.98 µg/mL, respectively. Among T2D patients, individuals with more severe degree, as classified by kinds of treatment and control of hyperglycemic markers, demonstrated lower levels of 1,5-AG compared to patients with less severity (p-value<0.001). A negative correlation was found between 1,5-AG and other hyperglycemic markers, including HbA1C (r=-0.591, p-value<0.001), fasting blood glucose (r=-0.431, p-value<0.0001), and fructosamine (r=-0.482, p-value<0.001). Levels of 1,5-AG showed an increasing trend, while fasting blood glucose and other hyperglycemic markers reduced over patients receiving treatment periods.
Conclusion: Monitoring 1,5-AG could be applied as an additional biomarker to strengthen diagnosis and provide efficacious follow-up on T2D patients.
Keywords
Full Text:
PDFReferences
Lim PC, Rajah R, Lee CY, Wong TY, Tan SSA, Karim SA. Systematic review and meta-analysis of diabetes knowledge among type 2 diabetes patients in Southeast Asia. Rev Diabet Stud 2021;17:82-9.
Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, et al. Japanese clinical practice guideline for diabetes 2016. J Diabetes Investig 2018;9:657-97.
King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999;48:643-8.
Koga M. 1,5-Anhydroglucitol and Glycated Albumin in Glycemia. Vol. 64. Amsterdam: Elsevier; 2014.
Lee JE. Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol. Ann Pediatr Endocrinol Metab 2015;20:74-8.
Armbruster DA. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 1987;33:2153-63.
Dandona P. Minimizing glycemic fluctuations in patients with type 2 diabetes: approaches and importance. Diabetes Technol Ther 2017;19:498-506.
Sakasai-Sakai A, Takata T, Suzuki H, Maruyama I, Motomiya Y, Takeuchi M. Immunological evidence for in vivo production of novel advanced glycation end-products from 1,5-anhydro-D-fructose, a glycogen metabolite. Sci Rep 2019;9:10194.
Ijiri M, Yoshinaga K, Kawaguchi H, Miyazaki N, Kawaguchi M, Fujimoto Y, et al. In vivo metabolism of 1, 5-Anhydro-d-fructose to 1, 5-Anhydro-d-glucitol. In Vivo 2023;37:1022-7.
Tazawa S, Yamato T, Fujikura H, Hiratochi M, Itoh F, Tomae M, et al. SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci 2005;76:1039-50.
Januszewski AS, Karschimkus C, Davis KER, O’Neal D, Ward G, Jenkins AJ. Plasma 1,5 anhydroglucitol levels, a measure of short-term glycaemia: assay assessment and lower levels in diabetic vs. non-diabetic subjects. Diabetes Res Clin Pract 2012;95:e17-9.
Dungan KM. 1,5-anhydroglucitol (GlycoMark™) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008;8:9-19.
Yamanouchi T, Akanuma Y. Serum 1,5-anhydroglucitol (1,5 AG): New clinical marker for glycemic control. Diabetes Res Clin Pract 1994;24:S261-8.
McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T, et al. Circulating 1,5-Anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia. Diabetes Care 2004;27:1859-65.
Buse JB, Freeman JLR, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-Anhydroglucitol (GlycoMark™): a short-term glycemic marker. Diabetes Technol Ther 2003;5:355-63.
Herman WH, Dungan KM, Wolffenbuttel BH, Buse JB, Fahrbach JL, Jiang H, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1, 5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1689-94.
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care 2019;42:S13-28.
Ministry of Health (Vietnam). Guidelines for diagnosis and treatment of type 2 diabetes. Decision No. 5481/QĐ-BYT. Hanoi: Health VMo; 2020.
Institute for Health Metrics and Evaluation. What causes the most deaths? What risk factors drive the most death and disability combined? [homepage on the Internet]. Seattle: Institute for Health Metrics and Evaluation; 2023 [cited 2023 Mar 26]. Available from: https://www.healthdata.org/research-analysis/health-by-location/profiles/vietnam
Nguyen CT, Pham NM, Lee AH, Binns CW. Prevalence of and risk factors for type 2 diabetes mellitus in Vietnam: a systematic review. Asia Pac J Public Health 2015;27:588-600.
Li WL, Zheng HC, Bukuru J, De Kimpe N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol 2004;92:1-21.
Ministry of Health (Vietnam). Guidelines for diagnosis and treatment of hypertension. Decision No. 3192/QĐ-BYT. Hanoi: Health VMo; 2010.
Minh HV, Tran HV, Khai PG, Phuoc DV, Nguyen TT, Le MT, et al. Highlights the 2021 VNHA/VSH-guidelines on diagnosis and management of hypertension in adults. In: Conference of the XIV Vietnam National Congress of Cardiology; 2021 Nov 16; Hanoi: National Convention Center, Vietnam. Hanoi: ResearchGate; 2022.
Umeda F, Yamauchi T, Ishii H, Nakashima N, Hisatomi A, Nawata H. Serum 1,5-anhydro-D-glucitol and glycemic control in patients with non-insulin-dependent diabetes mellitus. Tohoku J Exp Med 1991;163:93-100.
Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet 1996;347:1514-8.
Kwon PS, Rheem I. The Assessment of blood glucose distribution according to the fasting state and glycemic control indicators for diabetes screening. Korean J Clin Lab Sci 2016;48:312-20.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.